This further emphasizes that confirmation of the Philadelphia chromosome should still be followed-up by testing for CRLF2 overexpression or CRLF2 rearrangements since standard therapy for Ph+ ALL may be less effective in this situation. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.